Results 81 to 90 of about 53,966 (229)

Phase IIb Trial for the Palliative Treatment of Patients With Primary Hepatic Malignancy Unable to Receive Curative Treatment: Efficacy of Colchicine

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This trial was to evaluate the efficacy and the safety of colchicine for the palliative treatment of patients with primary hepatic malignancy unable to receive curative treatment. Forty hepatocellular carcinoma (HCC) patients and two intrahepatic cholangiocarcinoma (ICC) patients signed the informed consents.
Zu‐Yau Lin   +8 more
wiley   +1 more source

Nano Delivery Strategy Opens Effective Avenues for the Treatment of Colorectal Cancer

open access: yesMedicine Bulletin, EarlyView.
ABSTRACT Colorectal cancer (CRC) presents significant therapeutic challenges because of chemoresistance, systemic toxicity, and the complexity of the tumor microenvironment (TME). Nanodrug delivery systems (NDDS) have emerged as versatile platforms capable of overcoming these limitations by enhancing tumor accumulation, improving pharmacokinetics, and ...
Qiurong Wei   +7 more
wiley   +1 more source

Pharmacological Inhibition of APT2 by Solasonine Promotes Ferroptosis Through Palmitoylation Modulation in Gallbladder Cancer

open access: yesPhytotherapy Research, EarlyView.
Schematic illustration of SS‐induced ferroptosis through targeting APT2‐mediated STAT3 palmitoylation in GBC cells. ABSTRACT Gallbladder cancer (GBC), the most prevalent and lethal biliary tract malignancy, lacks effective therapeutic strategies. Solasonine (SS), a bioactive steroidal alkaloid derived from Solanum nigrum L, exhibits antitumor activity ...
Liu‐qing Shi   +12 more
wiley   +1 more source

Pedunculoside Inhibits Hepatocellular Carcinoma Progression by Activating the MAPK Signaling Pathway Through Targeting and Suppressing CDK4

open access: yesPhytotherapy Research, EarlyView.
Pedunculoside targets and suppresses CDK4; consequently, it activates the MAPK pathway and inhibits hepatocellular carcinoma progression. ABSTRACT Hepatocellular carcinoma (HCC) remains a major challenge in cancer prevention and treatment, highlighting the urgent need for effective and low‐toxicity anti‐HCC therapies. Recently, CDK4‐targeted inhibitors
Yang Zhou   +9 more
wiley   +1 more source

Immune escape mechanisms revealed by multifunctional nanoprobes targeting PD‐L1 in hepatic cancer progression

open access: yesVIEW, EarlyView.
The ICGB@Apt nanoprobes are designed to specifically recognize immune checkpoint molecules such as PD‐L1, thereby enabling precise monitoring of the progression from liver cirrhosis to HC. By binding to PD‐L1 on tumor cells, ICGB@Apt visualizes immune escape events and tumor metastasis while simultaneously reflecting the dynamic interaction between ...
Yiteng Meng   +5 more
wiley   +1 more source

Japanese Clinical Practice Guidelines for Vascular Tumors, Vascular Malformations, Lymphatic Malformations, and Lymphangiomatosis 2022

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT The objective was to prepare guidelines to perform the current optimum treatment by organizing effective and efficient treatments of hemangiomas and vascular malformations, confirming the safety, and systematizing treatment, employing evidence‐based medicine techniques and aimed at improvement of the outcomes.
Yoshiaki Kinoshita   +116 more
wiley   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

Targeting Wnt3a and Loxl2 Synergistically Induces Ferroptosis in Liver Cancer Stem Cells and Suppresses Tumorigenesis

open access: yesCancer Science, EarlyView.
Using bioinformatic analysis, LCSC models, and transgenic mice, we demonstrate that co‐inhibition of Wnt3a and Loxl2 potently triggers ferroptosis and inhibits orthotopic liver tumorigenesis. The enhanced antitumor effect upon dual targeting, mediated through ZEB1 upregulation, highlights a promising combinatory approach against HCC.
Guanghui Ren   +6 more
wiley   +1 more source

Intracellular magnetic hyperthermia reverses sorafenib resistance in hepatocellular carcinoma through its action on signaling pathways

open access: yesiScience
Summary: Sorafenib, a first-line drug for advanced hepatocellular carcinoma (HCC), unfortunately encounters resistance in most patients, leading to disease progression.
Hugang Li   +9 more
doaj   +1 more source

Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High‐Risk Hematological Malignancies

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Introduction Allogeneic stem cell transplantation (allo‐SCT) and donor lymphocyte infusions (DLI) can elicit a graft‐versus‐leukemia (GvL) effect in pediatric patients with hematological malignancies. We report our single‐center experience with prophylactic DLI in high‐risk pediatric patients with leukemia or lymphoma, focusing on feasibility,
Denise Epple   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy